David A. Siegel Myriad Genetics Inc Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Myriad Genetics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 288,000 shares of MYGN stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

288,000

Holding current value

$2.33 Million

% of portfolio

0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.84 - $8.84 $1.11 Million - $2.55 Million	288,000 New	288,000 $1.53 Million
Q2 2024 Aug 14, 2024	SELL	$17.98 - $25.47 $125,860 - $178,290	-7,000 Reduced 39.33%	10,800 $264,000
Q1 2024 May 15, 2024	SELL	$17.59 - $23.59 $73,878 - $99,078	-4,200 Reduced 19.09%	17,800 $379,000
Q4 2023 Feb 14, 2024	SELL	$13.91 - $21.32 $133,536 - $204,672	-9,600 Reduced 30.38%	22,000 $421,000
Q3 2023 Nov 14, 2023	BUY	$15.99 - $23.22 $161,499 - $234,522	10,100 Added 46.98%	31,600 $506,000
Q2 2023 Aug 14, 2023	SELL	$17.56 - $23.76 $57,947 - $78,408	-3,300 Reduced 13.31%	21,500 $498,000
Q1 2023 May 15, 2023	SELL	$15.26 - $23.75 $123,606 - $192,375	-8,100 Reduced 24.62%	24,800 $576,000
Q4 2022 Feb 14, 2023	SELL	$14.51 - $20.99 $34,824 - $50,375	-2,400 Reduced 6.8%	32,900 $477,000
Q3 2022 Nov 14, 2022	SELL	$18.21 - $27.88 $122,007 - $186,796	-6,700 Reduced 15.95%	35,300 $674,000
Q2 2022 Aug 15, 2022	SELL	$16.45 - $25.88 $258,265 - $406,316	-15,700 Reduced 27.21%	42,000 $763,000
Q1 2022 May 16, 2022	SELL	$22.67 - $28.01 $437,531 - $540,593	-19,300 Reduced 25.06%	57,700 $1.45 Million
Q4 2021 Feb 14, 2022	SELL	$24.13 - $32.63 $1.22 Million - $1.65 Million	-50,500 Reduced 39.61%	77,000 $2.13 Million
Q3 2021 Nov 15, 2021	SELL	$29.97 - $36.66 $7.69 Million - $9.41 Million	-256,700 Reduced 66.81%	127,500 $4.12 Million
Q2 2021 Aug 16, 2021	SELL	$25.39 - $32.61 $5.42 Million - $6.96 Million	-213,400 Reduced 35.71%	384,200 $11.7 Million
Q1 2021 May 17, 2021	SELL	$19.92 - $31.6 $2.6 Million - $4.13 Million	-130,700 Reduced 17.95%	597,600 $18.2 Million
Q4 2020 Feb 16, 2021	SELL	$12.16 - $19.77 $1.56 Million - $2.54 Million	-128,300 Reduced 14.98%	728,300 $14.4 Million
Q3 2020 Nov 16, 2020	BUY	$11.25 - $14.75 $2.69 Million - $3.52 Million	238,700 Added 38.63%	856,600 $11.2 Million
Q2 2020 Aug 14, 2020	BUY	$10.69 - $16.49 $5.47 Million - $8.43 Million	511,500 Added 480.73%	617,900 $7.01 Million
Q1 2020 May 15, 2020	BUY	$9.78 - $29.53 $1.04 Million - $3.14 Million	106,400 New	106,400 $1.52 Million
Q3 2019 Nov 14, 2019	SELL	$22.08 - $47.08 $262,752 - $560,252	-11,900 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$22.67 - $35.0 $269,773 - $416,500	11,900 New	11,900 $331,000
Q1 2019 May 15, 2019	SELL	$26.93 - $34.7 $210,054 - $270,660	-7,800 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$27.23 - $45.56 $212,394 - $355,368	7,800 New	7,800 $227,000
Q2 2018 Aug 14, 2018	SELL	$27.75 - $40.17 $269,119 - $389,568	-9,698 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$28.83 - $41.01 $7.8 Million - $11.1 Million	-270,614 Reduced 96.54%	9,698 $287,000
Q4 2017 Feb 14, 2018	SELL	$28.45 - $37.14 $6.45 Million - $8.41 Million	-226,548 Reduced 44.7%	280,312 $9.63 Million
Q3 2017 Nov 14, 2017	BUY	$24.01 - $36.2 $12.2 Million - $18.3 Million	506,860	506,860 $18.3 Million

Others Institutions Holding MYGN

# of Institutions

234

Shares Held

95.2M

Call Options Held

460K

Put Options Held

14.2K

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $652M
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account